| Autor: |
Manuel Alfredo Podestà, Federica Mescia, Anna Ricchiuto, Rona Smith, Martina Tedesco, Matthias Arnaldo Cassia, Julia Holle, Renato Alberto Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Zdenka Hruskova, Vladimir Tesar, Gianmarco Sabiu, Maurizio Gallieni, Maria C Cid, Augusto Vaglio, Lorraine Harper, Mario Cozzolino, Francesco Scolari, David Jayne, Federico Alberici |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG ≤7 g/l at 6 months. Results The study included 227 patients. IgG levels at 6 months were lower than baseline (P Conclusions In AAV patients treated with rituximab, hypogammaglobulinemia at 6 months after induction is common, and lower IgG levels are associated with serious infections. The risk of hypogammaglobulinemia in these patients increases with age and higher glucocorticoid doses. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
